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Background: miR-15a and miR-16-1 have been identified as tumor suppressor genes in prostate 
cancer, but their safe and effective delivery to target cells is key to the successful use of this 
therapeutic strategy. RNA aptamer A10 has been used as a ligand, targeting prostate cancer cells 
that express prostate-specific membrane antigen (PSMA). Compared with A10, the binding of 
the second-generation RNA aptamer, A10-3.2, to PSMA is more efficient.
Methods: A10-3.2 was investigated as a PSMA-targeting ligand in the design of a polyami-
doamine (PAMAM)-based microRNA (miR-15a and miR-16-1) vector to prostate cancer cells. 
Using polyethyleneglycol (PEG) as a spacer, PAMAM was conjugated to aptamer (PAMAM-
PEG-APT) and used as a vehicle for miRNA target delivery.
Results: Luciferase assays of pGL-3 expression against PC3 (PSMA-) and LNCaP (PSMA+) 
cells demonstrated that the transfection efficiency of the synthesized DNA/PAMAM-PEG-APT 
complex was higher than that of the DNA/PAMAM-PEG complex. In addition, cell viability 
assays of LNCaP (PSMA+) cells showed that, with a N/P ratio of 15:1, the IC50 value of miRNA/
PAMAM-PEG-APT was approximately 4.7-fold lower than that of miRNA/PAMAM-PEG.
Conclusion: This PSMA-targeted system may prove useful in widening the therapeutic window 
and allow for selective killing of prostate cancer cells.
Keywords: miRNA, aptamer, polyamidoamine, prostate-specific membrane antigen, targeted 
delivery, prostate cancer
Introduction
Aptamers, ie, RNA or DNA oligonucleotides,1,2 are ligands that can bind target 
antigens with high affinity and specificity3 by folding into unique three-dimensional 
conformations.4,5 Aptamer A106 is a RNA aptamer that can bind to the extracellular 
domain of the prostate-specific membrane antigen (PSMA) commonly found on 
the cell surface of prostate cancer cells. Its capability for active binding and uptake 
by targeted cancer cells in vitro has been demonstrated.7–10 However, aptamer A10 
has some shortcomings, such as difficult chemical synthesis, low stability, and low 
activity in vivo, which limit its efficacy for tumor-specific treatment. The second-
generation aptamer, A10-3.2, has been synthesized recently to optimize aptamer A10.11 
Aptamer A10-3.2 is obtained by truncating aptamer A10 from 71 to 39 nucleotides. 
Compared with aptamer A10, aptamer A10-3.2 is easily synthesized chemically, has 
enhanced silencing activity and specificity, and its in vivo kinetics can be optimized 
by modification.
A10-polyethylene glycol (PEG)-polyethyleneimine (PEI) has been synthesized 
recently and used as a target-specific intracellular delivery carrier for small interfering International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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RNA (siRNA) in the treatment of prostate cancer.12 Although 
PEG-modified PEI has lower toxicity, its biological toxicity 
in vivo remains a difficult problem to tackle.13–16 For this 
reason, we chose a new material polyamidoamine (PAMAM) 
to replace PEI. PAMAM is a novel class of nanoscopic and 
spherical polymer that has been proven to be an efficient 
gene carrier.17 Positively charged PAMAM with primary 
amino surface groups has the inherent ability to associate 
with and condense RNA, and has been used for biocom-
patible and highly effective siRNA delivery.18,19 PAMAM 
encapsulated gold nanorods can enhance charge transfer and 
biocompatibility.20–22 Therefore, we used aptamer A10-3.2 
as the PSMA-targeting ligand in our study to construct an 
aptamer-conjugated PAMAM in an attempt to achieve an 
efficiently targeted gene delivery to prostate cancer cells.
siRNA has been widely used for the treatment of prostate 
cancer. However, given that prostate cancer is the combined 
effect of disordered expression of multiple genes, single use 
of siRNA targeting specific genes is often ineffective.23–25 
There are obvious difficulties using the RNA interference 
technique, but microRNA can solve these problems effec-
tively. Recent reports26–29 show that miR-15a and miR-16-1 
act as tumor suppressor genes in prostate cancer, and associ-
ate with the expression of BCL2, CCND1, and WNT3 A, thus 
promoting survival, proliferation, and invasion in prostate 
cancer cells. Therefore, the delivery of miR-15a and miR-
16-1 could be useful for the treatment of prostate cancer.
In our study, aptamer A10-3.2 was used as a new ligand 
conjugated with PAMAM via bifunctional PEG to carry 
miR-15a and miR-16-1 and form an efficient PSMA-targeting 
system (miRNA/PAMAM-PEG-APT). A PSMA-positive 
prostate cancer cell line, LNCaP (PSMA+), was used as 
the model cell line, and a PSMA-negative prostate cancer 
cell line, PC3 (PSMA-), was used as a control to determine 
the specificity of the delivery system. The characteristics 
and anticancer effect of miRNA/PAMAM-PEG-APT were 
investigated in vitro.
Materials and methods
Materials
Materials used in this study were: PAMAM dendrimer 
(generation 5, 5% w/w solution in methyl alcohol, contain-
ing 128 surface primary amino groups [molecular weight 
28,826]); dithiothreitol (DTT, Sigma-Aldrich, St Louis, 
MO); α-malemidyl-ω-N-hydroxysuccinimidyl polyethyl-
eneglycol (NHS-PEG-MAL, molecular weight 3400, Nektar 
Therapeutics, Huntsville, AL); DyLight-633 NHS ester and 
micro-bicinchoninic acid protein assay kit (Pierce, Rockford, 
IL); plasmid pEGFP-N2 (Clontech, Palo Alto, CA) and a 
  pGL3-control vector (Promega, Madison, WI) purified from 
bacteria using a Qiagen plasmid mega kit (Qiagen GmbH, 
Hilden, Germany); system and reporter lysis buffer (Promega); 
prostate carcinoma PC3 and LNCaP cell lines   (American Tis-
sue Type Culture); anti-PSMA aptamer (sequence 5′-GGGA
GGACGAUGCGGAUCAGCCAUGUUUACGUCACUCC
U-(CH2)6-S-S-(CH2)6-OH-3′ with 2′-fluoro pyrimidines) and 
nuclease-free water (RiboBio, Guangzhou, China); miRNA-
15a (sequence 5′-UAGCAGCACAUAAUGGUUUGUG-3′ 
with 2′-fluoro pyrimidines); miRNA-16-1 (sequence 
5′-UAGCAGCACGUAAAUAUUGGCG-3′  with 
2′-fluoro pyrimidines), and negative control-miRNA 
(sequence 5′-UUCUCCGAACGUGUCACGUUTT-3′ with 
2′-fluoropyrimidines, GenePharma, Shanghai, China). All 
the other materials were reagent grade and obtained from 
commercial sources.
synthesis of PAMAM-Peg  
and PAMAM-Peg-APT
A 1:2 conjugate of PAMAM and NHS-PEG3400-MAL was 
prepared by a specific reaction between the primary amino 
groups on the surface of PAMAM and the NHS groups 
of the bifunctional PEG derivative (nPAMAM:nNHS-
PEG3400-MAL = 1:2). The reaction was then performed in 
phosphate-buffered solution (pH 8.0) for 15 minutes at room 
temperature. The resulting conjugate, PAMAM-PEG, was 
purified by ultrafiltration using a 5 kDa molecular weight 
cutoff membrane to remove unreacted PEG, and the buffer 
was exchanged into phosphate-buffered solution (pH 7.0). 
The purified PAMAM-PEG obtained was lyophilized and 
stored at 4°C for use.
To prepare 3′-SH-modified aptamer (SH-APT), 0.1 µmol 
OH-(CH2)6-S-S-(CH2)6-APT was dissolved in 2.5 mL 
100 mM DTT (pH 8.0), and incubated at room temperature 
for 30 minutes. The entire sample was loaded onto a Glen 
Gel-Pak™ 2.5 (Glen Research, Sterling, VA) desalting 
column, equilibrated with 25 mL 50 mM sodium phosphate 
(pH 6.0), allowed to drip through, and eluted with 2.5 mL 
sodium phosphate (pH 6.0). Finally, the purified conjugation 
of SH-APT was collected.
To conjugate the anti-PSMA aptamer with PAMAM-
PEG, 0.2 µmol MAL-activated PAMAM-PEG was dissolved 
in 3 mL nuclease-free phosphate-buffered solution (pH 7.0), 
reacted with 0.1 µmol SH-APT for 12 hours at 4°C, and the 
resulting product, PAMAM-PEG-APT, was purified by ultra-
filtration using a 20 kDa molecular weight cutoff membrane 
to remove unreacted aptamer and suspended in nuclease-free International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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water. The anti-PSMA aptamer-conjugated PAMAM-PEG 
(PAMAM-PEG-APT) was stored at 4°C. For the synthesis of 
DyLight-633-labeled conjugate, PAMAM was first reacted 
with DyLight-633 in 100 mM NaHCO3 for 12 hours at 4°C, 
purified and identified as described previously.26 The cor-
responding conjugate, DyLight-633-labeled PAMAM-  PEG-
APT, was synthesized as described previously.
characterization of PAMAM derivatives
The characteristics of PAMAM derivatives were deter-
mined by nuclear magnetic resonance (NMR) spectroscopy. 
PAMAM, PAMAM-PEG, and PAMAM-PEG-APT were 
solubilized in D2O and determined in a 300 mHz spectrometer 
(Varian, Palo Alto, CA).
cellular uptake of DyLight-633-labeled  
dendrimers in Pc3 and LNcaP
PC3 and LNCaP were seeded at a density of 8 × 104 cells/
well in six-well plates (Corning-Coaster, Tokyo, Japan), 
cultured for 72 hours, and checked under the microscope for 
confluency and morphology. Wells with a similar cell density 
were chosen for the experiments. PC3 and LNCaP were then 
incubated with DyLight-633-labeled PAMAM-PEG-APT in 
a PAMAM concentration range of 0.04–1.20 µM for 60 min-
utes. Cells were washed three times with phosphate-buffered 
solution (pH 7.4) and visualized under a DMIL fluorescent 
microscope (Leica Camera AG, Solms, Germany). For quan-
titative analysis, PC3 and LNCaP treated as described above 
was trypsinized and centrifuged at 1600 rpm for 8 minutes 
to obtain a cell pellet, which was subsequently resuspended 
in phosphate-buffered solution (pH 7.4) and analyzed using 
a flow cytometer (FACSCalibur, San Jose, CA) equipped 
with an argon ion laser (638 nm) as the excitation source. 
The fluorescence intensity of DyLight-633 was collected at 
658 nm. For each sample, 10,000 events were collected and 
data were analyzed by CellQuest software. Untreated PC3 
and LNCaP served as the control. Living cells were defined 
by gating the major population of cells, and only cells within 
this gate were analyzed. The mean fluorescence intensity of 
the cells was calculated using a histogram plot.
Preparation of DNA/PAMAM-Peg-APT  
complexes
DNA/PAMAM-PEG-APT complexes were prepared by 
gently mixing (6 µg/pEGFP/500 µL DI water) with various 
amounts of polymer stock solution, corresponding to N/P 
ratios ranging from 1 to 25, into a final volume of 1000 µL. 
The complexes were incubated for 30 minutes at room 
  temperature prior to analysis. The sizes and zeta potentials of 
DNA/PAMAM-PEG-APT complexes formed in phosphate-
buffered saline (10 mM, pH 7.4) at various N/P ratios (1–25) 
were measured in triplicate using a Zetasizer Nano-ZS90 
(Malvern Instruments Ltd, Worcestershire, UK).
Efficiency of gene expression in PC3  
and LNcaP
PC3 and LNCaP cell lines were cultured in RPMI 
1640 medium (Gibco, Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum and 1% antibiotics at 
37°C in a humidified atmosphere with 5% CO2. PC3 and 
LNCaP cells were seeded into six-well plates (Corning-
Coaster, Tokyo, Japan) at a density of 3 × 105 cells per well 
and incubated at 37°C for 24 hours (to reach 70% conflu-
ence) prior to transfection. Complexes containing 3 µg DNA, 
with PAMAM to DNA at various N/P ratios (1–25), were 
added to the cells in fetal bovine serum-free medium, and the 
mixture was incubated at 37°C for 1 hour. After 48 hours, 
fluorescence images of the gene expression products, ie, 
green fluorescent protein, were acquired and photographed 
under a fluorescence microscope. The efficiency of gene 
transfer was quantitatively determined by luciferase activity 
using the pGL3-control vector. After 48 hours of transfec-
tion, activity of the gene expression product, luciferase, 
was quantified using a luciferase assay system (Promega) 
following the manufacturer’s instructions. Briefly, cells 
were firstly lysed in 150 µL 1 × cell culture lysis reagent for 
30 minutes at room temperature, the luciferase activity was 
measured by a luminometer (Promega E6080), and finally the 
protein content was measured using a micro-bicinchoninic 
acid protein assay kit.
Western blot analysis
To assess the downregulation of Bcl-2, Cyclin D1, and 
Wnt3a gene in LNCaP cells, cells were transfected with 
miRNA(miRNA-15a:miRNA-16-1 = 1:1)/PAMAM-PEG-
APT complexes and negative control-miRNA (NC-miRNA)/
PAMAM-PEG-APT complexes. Cells were harvested at 24, 
48, and 72 hours post-transfection and lysed in cold RIPA 
buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EGTA, 
and 0.25% sodium deoxycholate), and then the lysate was 
incubated for 15 minutes at 4°C and removed by centrifu-
gation at 12,000 rpm for 15 minutes. The supernatant was 
analyzed for protein concentrations using the Bradford 
assay   (Bio-Rad, Hercules, CA). An equal amount (10 mg) 
of protein was subjected to electrophoresis on sodium 
dodecyl sulfate-polyacrylamide gels and then transferred International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 NMr spectra of (A) PAMAM, (B) PAMAM-Peg, and (C) PAMAM-Peg-APT in D2O at 300 mhz.
Abbreviations: PAMAM, polyamidoamine; Peg, polyethylene glycol; APT, aptamer.
to   polyvinylidene fluoride membrane (Millipore, Billerica, 
MA). The blotted membrane was immunostained with 
antibodies specific to anti-Bcl-2 (BioWorld, Visalia, CA), 
anti-Cyclin D1 (BioWorld) and anti-Wnt3a antibodies (R&D 
Systems Inc, Minneapolis, MN). Blots were developed by 
the enhanced chemiluminescence reagents (Amersham 
Pharmacia, Buckinghamshire, UK) and visualized by the 
Gene-Genius   Imaging System (Syngene, Frederick, MD).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In vitro anticancer effect
The antiproliferation effect of miRNA/PAMAM-PEG-APT 
on LNCaP and PC3 cells was evaluated by a cell counting 
kit-8 (CCK-8, Dojindo, Japan). LNCaP cells and PC3 cells 
were seeded in 96-microwell plates at a density of 1 × 104 
cells per well and incubated at 37°C for 24 hours. Cells 
were treated with various concentrations (0.02–50 µM) 
of complexes: miRNA(miRNA-15-a:miRNA-16-1 = 1:1)/
PAMAM-PEG-APT, NC-miRNA/PAMAM-PEG-APT and 
miRNA (miRNA-15-a:miRNA-16-1 = 1:1)/PAMAM-PEG 
for 72 hours. After that, 10 µL of CCK-8 was added to each 
well and incubated for another 2 hours. The absorbance of 
each well was determined with a microplate reader (Thermo 
Scientific, Rockford, IL) and a standard curve was drawn 
according to the absorbance and cell number, and each sam-
ple was tested in triplicate. The antiproliferation effect was 
expressed as the IC50 value as the concentration that inhibits 
cell growth by 50% as compared with nontreated   controls. 
IC50 value was calculated according to the equation: 
y = bottom × (top-bottom)/[1 + 10(logIC50-x) × Hill slope], where 
bottom and top are the minimum and maximum y-axis val-
ues, respectively, of a plateau in the curve, and Hill slope 
is the steepness of the curve using GraphPad 5.0 PRISM® 
(GraphPad Software Inc, San Diego, CA).
statistical analysis
The data were presented as means ± standard deviation. 
Statistically significant differences were determined using 
two-sample t-tests and analysis of variance, with P , 0.05 
as the significance level.
Results and discussion
characterization of PAMAM derivatives
The solvent peak of D2O was found at 4.65 ppm (Figure 1). 
The methylene protons of branching units of PAMAM 
had multiple peaks between 2.2 and 3.4 ppm (Figure 1A), 
which is consistent with the NMR spectrum of PAMAM 
(generation = 5) reported previously.30 The NMR spectrum 
of PAMAM-PEG had multiple peaks of the repeat units 
in PEG at 3.5 ppm and a characteristic peak of the MAL 
group in PEG at 6.7 ppm (Figure 1B), confirming conjuga-
tion of PEG to PAMAM. However, the MAL peak disap-
peared in the NMR spectrum of PAMAM-PEG-APT, even 
when the repeat units of PEG still presented a sharp peak 
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at 3.5 ppm (Figure 1C), indicating that the MAL group had 
reacted with the thiol group of SH-APT. The NMR spectra 
demonstrated successful synthesis of PAMAM-PEG-APT. 
In addition, the integrated areas of NMR peaks were used 
to quantify the number of PEG chains per PAMAM, with 
the assumption of 280 methylene protons per PEG and 
2032 per PAMAM. As shown in Figure 1B, PAMAM-
PEG had a PAMAM/PEG proton ratio of 0.74, implying 
an average of 2.1 PEG chains per PAMAM. In our study, 
we used the small hairpin method to modify aptamers so 
that aptamers could connect to PAMAM under mild condi-
tions, thus maintaining optimal biological activity of the 
aptamers and avoiding loss of the target. The synthesis 
was made simple by using PEG as a linker. In addition, 
a long circulation was ensured, because parts of the PEG 
were not connected to the aptamers.
cellular uptake of DyLight-633-labeled  
dendrimers in Pc3 and LNcaP
The results of cellular uptake for DyLight-633-labeled 
dendrimers are shown using fluorescent images and quanti-
fied with a percentage of DyLight-633 positive cells. The 
  fluorescence intensity corresponded to that of the DyLight-
633-labeled PAMAM-PEG-APT concentrations (Figure 2). 
After exposure of PC3 and LNCaP to different concentrations 
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Figure 3 sizes and zeta potentials of pegFP/PAMAM-Peg-APT complexes at various N/P ratios.
Abbreviations: PAMAM, polyamidoamine; Peg, polyethylene glycol; APT, aptamer.
of DyLight-633-labeled PAMAM-PEG-APT (0.04–1.20 µM) 
for 60 minutes, the percentage of DyLight-633-positive PC3 
and LNCaP cells increased from 16.97% to 59.07% and from 
30.61% to 89.91%, respectively   (Figure 2B). The percentage 
of DyLight-633-positive LNCaP cells of PAMAM-PEG-APT 
was much higher than that of PC3 cells at each concentra-
tion (Figure 2B), suggesting that conjugation of aptamer 
facilitated uptake of the vector by LNCaP more efficiently. 
Because the surfaces of the PC3 cells had low expression 
of PSMA, aptamers could not be mediated by PAMAM-
PEG-APT into the cells, resulting in lower efficiency than 
for LNCaP.
characterization of DNA/PAMAM- 
Peg-APT complexes
In our study, we used PEG as a spacer between PAMAM 
and aptamer to disperse dendrimer molecules by increas-
ing hydrophilicity and reducing nonspecific interactions 
with the cellular membrane.31 Aptamer was coupled to 
the remote end of the PEG chain, triggering the receptor-
mediated mechanism to increase the accumulation of DNA/
PAMAM-PEG-APT in prostate cancer. The sizes and zeta 
potentials of the pEGFP/PAMAM-PEG-APT complexes 
were analyzed using the Zetasizer Nano-ZS90 over a range 
of N/P ratios. As shown in Figure 3, the average size of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the pEGFP/PAMAM-PEG-APT complexes decreased and 
the zeta potential increased with increasing N/P ratios. At 
higher N/P ratios, the smaller size resulted from forma-
tion of more compact structures, owing to the higher ionic 
  interactions and the net electrostatic repulsive forces between 
the complexes.
Efficiency of gene expression in PC3 
(PsMA-) and LNcaP (PsMA+)
To observe the targeted delivery and transfection efficiency of 
PAMAM-PEG-APT in PSMA-overexpressing cells, LNCaP 
cells and PC3 cells were treated with DNA/PAMAM-PEG 
and DNA/PAMAM-PEG-APT complexes in series of N/P 
ratios using 3 µg pEGFP (Figure 4A) or pGL3-Control Vector 
(Figure 4B). The result of luciferase activity assay indicated 
that DNA/PAMAM-PEG-APT complexes resulted in higher 
gene expression than the DNA/PAMAM-PEG complexes 
in LNCaP cells, whereas the gene expression was rarely 
observed in PC3 cells transfected by DNA/PAMAM-PEG-
APT complexes at various N/P ratios. As shown in Figure 4B, 
the luciferase activity of PAMAM-PEG-APT (1.195906 × 106 
units/mg protein) was six-fold higher than that of PAMAM-
PEG (1.82086 × 105 units/mg protein) in LNCaP cells at a 
N/P ratio of 15, but no difference was observed in PC3 cells. 
This might attribute to the targeting head group aptamer, 
which could enhance the transfection efficiency by selec-
tively binding to PSMA-overexpressing cells through the 
aptamer-mediated approach.32 The strong positive charges 
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of the complexes provided higher transfection efficiency but 
also could induce cytotoxicity by disrupting and solubiliz-
ing cell membranes.33 To balance the high gene expression 
with cytotoxicity, we set the optimal N/P ratio at 15 for the 
synthesis of DNA/PAMAM-PEG-APT complexes.
Western blot analysis
Figure 5 shows the results of Western blot of Bcl-2, Cyclin 
D1, and Wnt3a, the direct target of miRNA-15a and miRNA-
16-1,26 which were determined at 24, 48, and 72 hours fol-
lowing transfection. Their expression began decreasing after International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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48 hours of miRNA transfection, and decreased significantly 
after 72 hours, especially for Wnt3a, whereas this phenom-
enon was rarely observed in NC-miRNA transfection. Thus, 
downregulation of Bcl-2, Cyclin D1, and Wnt3a by the deliv-
ery of miRNA, whose functions are directly associated with 
cancer progression and invasion,26 is expected to increase cell 
apoptosis. It has been demonstrated that PAMAM-PEG-APT 
can carry miRNA effectively into cells to have an inhibitory 
effect, so use of miR-15a and miR-16-1 in the treatment of 
prostate cancer may become a reality.
In vitro anticancer effect
To evaluate the anticancer potential of miRNA/PAMAM-
PEG-APT, we performed a series of in vitro cytotoxicity 
assays using the CCK8 assay to determine the IC50 value. 
LNCaP cells were treated with miRNA/PAMAM-PEG-APT, 
NC-miRNA/PAMAM-PEG-APT, and miRNA/PAMAM-
PEG complexes (0.02–50 µM). The results show that cell 
growth was inhibited in a dose-dependent manner (Figure 6). 
The calculated IC50 value was 0.0144 µM, 0.788 µM, and 
556.47 µM, respectively. Therefore, miRNA/PAMAM-
PEG-APT had an approximately 5.47-fold lower IC50 value 
than miRNA/PAMAM-PEG. It could be concluded from 
the experimental results of cellular uptake of DyLight-633
-labeled dendrimers and efficiency of gene expression in 
LNCaP as described earlier that PAMAM-PEG-APT could 
raise the gene transfection rate in LNCaP, so we may infer 
that PAMAM-PEG-APT could carry more miRNA into 
LNCaP. In addition, the results of Western blot analysis 
showed that the more miRNA was carried into LNCaP, the 
further Bcl-2, Cyclin D1, and Wnt3a were downregulated, 
which explains why miRNA/PAMAM-PEG-APT had a 
lower IC50 value. Thus, there is reason to believe that miRNA/
PAMAM-PEG-APT could become a novel nanotargeted drug 
delivery system for the treatment of prostate cancer.
Conclusion
In this study, we successfully constructed an efficient target 
gene delivery system mediated by the second-generation 
aptamer (PAMAM-PEG-APT), which could synergistically 
induce selective cell death of prostate cancer cells by loading 
miR-15a and miR-16-1. PAMAM-PEG-APT could effectively 
deliver miRNA to prostate cancer cells overexpressing PSMA, 
resulting in tumoricidal efficacy as verified by cell viability 
assays. It should be emphasized that because PAMAM-PEG-
APT uses the second-generation APT A10-3.2, synthesis of the 
system becomes much easier and biological targeting becomes 
even stronger. In addition, use of PAMAM decreases toxicity 
of the system and endows it with better biocompatibility. 
Replacement of siRNA with miRNA provides multiple-target 
inhibition of prostate cancer and enhances the anticancer 
effect of the system. Therefore, this research may prove to 
be a significant contribution to the use of nanocarrier-based 
targeted delivery of miRNAs for the treatment of cancer.
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